RecruitingPHASE1, PHASE2NCT04752826
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Studying Gonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioInvent International AB
- Principal Investigator
- Andres McAllister, PhDBioInvent International AB
- Intervention
- BI-1808(drug)
- Enrollment
- 176 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (25)
- City of Hope National Medical Center, Duarte, California, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Rigshospitalet, Copenhagen, Denmark
- Herlev Hospital, Herlev, Denmark
- PRA Health Sciences - Hungary, Budapest, Hungary
- Magyar Honvédség-Egészségügyi Központ, Budapest, Hungary
- Debreceni Egyetem Klinikai Központ, Debrecen, Hungary
- Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser, Omsk, Russia
- National Medical Research Center VA Almazov, Saint Petersburg, Russia
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
- Institut Catala d'oncologia. Hospital Duran I Reynals, Barcelona, Spain
- Hospital General Universitario Gregorio Marañon, Madrid, Spain
- START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- +10 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04752826 on ClinicalTrials.govOther trials for Gonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc.
- RECRUITINGNCT05645510LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyUniversity of Alberta
- RECRUITINGNANCT05142982Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced SeminomaTata Memorial Centre
- RECRUITINGNANCT05053230A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04205227ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsENB Therapeutics, Inc
- ACTIVE NOT RECRUITINGPHASE1NCT03872947A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, Inc
- RECRUITINGNANCT03787056Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon
- ACTIVE NOT RECRUITINGNANCT03418844Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of ChemotherapyCentre Francois Baclesse